WHAT: EnVivo Pharmaceuticals to share results from its Ib/IIa
trial in Alzheimer's disease patients with its
nicotinic alpha-7 agonist EVP-6124.
WHEN: Wednesday, July 15, 2009.
WHERE: Alzheimer's Association 2009 International Conference
on Alzheimer's Disease (ICAD) in Vienna, Austria.
WHO: Dana Hilt, MD, senior vice president, clinical
development and chief medical officer, EnVivo
Pharmaceuticals.
ADDITIONAL: EVP-6124 is EnVivo's novel alpha-7 nicotinic
acetylcholine receptor agonist currently in development
for Alzheimer's disease and cognitive dysfunction
associated with schizophrenia. In this trial, safety
and effects on cognition of EVP-6124 were tested in
Alzheimer's patients already on long term treatment
with acetylcholine esterase inhibitors.

About EnVivo Pharmaceuticals

EnVivo Pharmaceuticals, located in Watertown, Mass., is a biopharmaceutical company dedicated to discovering and developing small molecule therapeutics for disorders of the central nervous system, with a current focus on Alzheimer's disease, Cognitive Disorders and Schizophrenia. The company's lead product is an alpha-7 nicotinic acetylcholine receptor agonist and has been tested in Phase 2a clinical trials for cognition disorders in Alzheimer's disease and Schizophrenia. The company's other programs include an epigenetics program based on Histone Deacetylase inhibition (HDACi) with EVP-0334 as the lead molecule for cognition in Alzheimer's disease which is in Phase 1 studies, and several preclinical programs such as a Gamma Secretase Modulator (for Alzheimer's disease) and a PDE10 inhibitor program (for Schizophrenia). For more information aboutEnVivo, visitwww.envivopharma.com.

(Date:12/9/2016)... (PRWEB) , ... December 09, 2016 , ... ... Ball at The Pierre Hotel in New York, NY, on December 3rd, to ... dignitaries and physicians attended the annual event, which raised over $1 million - ...

(Date:12/8/2016)... WV (PRWEB) , ... December 08, 2016 , ... ... it will become Quality Insights beginning January 1, 2017. The name change ... its commitment to measuring and improving health care quality. , “We are very ...

(Date:12/8/2016)... ... 2016 , ... With the increasing demand for dental implants, the National Association ... to inform dentists and patients about the safety issues related to dental restorations. According ... the U.S. is projected to reach $6.4 billion in 2018 with more than 30 ...

(Date:12/8/2016)... VIEW, Calif. , Dec. 8, 2016 IRIDEX ... intends to offer newly issued shares of common stock, $0.01 ... pursuant to an underwritten public offering. The final terms of ... the time of pricing, and there can be no assurance ... IRIDEX expects to use the net proceeds it ...

(Date:12/8/2016)... -- The global biosurgery market is expected to grow at ... 2016 to 2021. The market is poised to reach ... in 2016. The market is primarily driven by rising ... and spinal problems, increasing clearance of biosurgery products by ... management. In this report, the biosurgery market ...